PAI-1 donor polymorphism influences long-term kidney graft survival

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3325-3332

  Rérolle, Jean Philippe ^a   Munteanu, Elisa ^a   Drouet, Mireille ^a   Szelag, Jean Christophe ^a   Champtiaux, Béatrice ^a   Yagoubi, Fatima ^a   Preux, Pierre Marie ^a   Aldigier, Jean Claude ^a   Le Meur, Yann ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic allograft nephropathy; Gene polymorphism; PAI 1; Renal transplantation

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL;

ADULT; BASE SEQUENCE; DNA PRIMERS; FEMALE; GENOTYPE; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TIME FACTORS; TISSUE DONORS; YOUNG ADULT;

EID: 52449096931     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn241     Document Type: Article

References (22)

1. Solez K, Colvin RB, Racusen LC et al. Banff 2005 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy. Am J Transplant 2007; 7(3): 518-526
2. Massy ZA, Guijarro C, Wiederkehr MR et al. Chronic renal allograft rejection: immunologic and non immunologic risk factors. Kidney Int 1996; 49: 518-524
3. Rerolle JP, Hertig A, Nguyen G et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenosis. Kidney Int 2000; 58: 1841-1850
4. Wang Y, Pratt JR, Hartley B et al. Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic allograft failure. Kidney Int 1997; 52: 371-377
5. Delarue F, Hertig A, Alberti C et al. Prognostic value of plasminogen activator inhibitor type 1 mRNA in microdissected glomeruli from transplanted kidneys. Transplantation 2001; 72: 1256-1261
6. Grandalliano G, Di Paolo S, Monno R et al. Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy. Transplantation 2001; 72: 1437-1443
7. Verpooten GA, Cools FJ, Van Der Planken MG et al. Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant 1996; 11(2): 347-351
8. Lahlou A, Peraldi MN, Thervet E et al. Chronic graft dysfunction in renal transplant patients: potential role of Plasminogen activator inhibitor type 1. Transplantation 2002; 73: 1290-1295
9. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence andmechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012
10. Ma LJ, Nakamura S, Aldigier JC et al. Regression of glomerulosclerosis with high dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor 1. J Am Soc Nephrol 2005; 16: 966-976
11. Dawson S, Hamsten A, Wiman B et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-190
12. Reis K, Arinsoy T, Derici U et al. Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. Clin Transplant 2005; 19(1): 10-14
13. Miller SA, Dykes DD, Poesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 1988; 16: 1215
14. Hoffmann S, Park J, Jacobson LM et al. Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int 2004; 66: 1686-1693
15. Brown KB, Kondeatis E, Vaughan RW et al. Influence of donor C3 allotype one late renal transplantation outcome. N Engl J Med 2006; 354: 2014-2023
16. Akalin E, Murphy B. Gene polymorphisms and transplantation. Curr Opin Immunol 2001; 13: 572-576
17. Chow KM, Szeto CC, Szeto CYK et al. Plasminogen activator inhibitor-1 polymorphism is associated with progressive renal dysfunction after acute rejection in renal transplant recipients. Transplantation 2002; 74: 1791-1794
18. Hauser IA, Schaeffeler E, Gauer S et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporin-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16(5): 1501-1511
19. Revelo MP, Federspiel C, Helderman H et al. Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma. Nephrol Dial Transplant 2005; 20(12): 2812-2819
20. Malyszko J, Malyszko JS, Pawlak K et al. The coagulo-lytic system and endothelial function in cyclosporin-treated kidney allograft recipients. Transplantation 1996; 62: 828-830
21. Van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functionnal analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci 1988; 85: 5525-5529
22. Sartori MT, Rigotti P, Marchini F et al. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunusuppression therapy. Transplantation 2003; 75(7): 994-998